NVNO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVNO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
enVVeno Medical's average Accounts Receivable for the three months ended in Dec. 2024 was $0.00 Mil. enVVeno Medical's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.
The historical rank and industry rank for enVVeno Medical's Days Sales Outstanding or its related term are showing as below:
During the past 10 years, enVVeno Medical's highest Days Sales Outstanding was 376.77. The lowest was 11.15. And the median was 45.46.
enVVeno Medical's Days Sales Outstanding stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).
The historical data trend for enVVeno Medical's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
enVVeno Medical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Sales Outstanding | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Medical Devices subindustry, enVVeno Medical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
enVVeno Medical's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as
Days Sales Outstanding (A: Dec. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2023 ) | + | Accounts Receivable (A: Dec. 2024 )) | / | count ) | / | Revenue (A: Dec. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
enVVeno Medical's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:
Days Sales Outstanding (Q: Dec. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Sep. 2024 ) | + | Accounts Receivable (A: Dec. 2024 )) | / | count ) | / | Revenue (A: Dec. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical (NAS:NVNO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of enVVeno Medical's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Francis Duhay | director | HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618 |
Robert Gray | director | 70 DOPPLER, IRVINE CA 92618 |
Sanjay Shrivastava | director | HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618 |
Matthew Jenusaitis | director | 2 GOODYEAR, IRVINE CA 92618 |
Robert Andrew Berman | director, officer: CEO | C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025 |
Hamed Alavi | officer: Chief Technology Officer | ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618 |
Marc H. Glickman | officer: See Remarks | 70 DOPPLER, IRVINE CA 92618 |
Biodyne Holding, S.a. | 10 percent owner | 13 RUE DE LA GARE, MORGES V8 1110 |
Craig Glynn | officer: Chief Financial Officer | 70 DOPPLER, IRVINE CA 92618 |
Marcus W. Robins | director | C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618 |
Robert A Rankin | officer: Chief Financial Officer | 9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069 |
Browston Trading Ltd | 10 percent owner | P.O. BOX 20533, NICOSIA G4 1660 |
Robert W. Doyle | director | 70 DOPPLER, IRVINE CA 92618 |
Robert A. Anderson | director | 70 DOPPLER, IRVINE CA 92618 |
Susan Montoya | officer: See Remarks | 70 DOPPLER, IRVINE CA 92618 |
From GuruFocus
By ACCESSWIRE • 11-27-2024
By ACCESSWIRE • 12-16-2024
By ACCESSWIRE • 09-27-2024
By GuruFocus News • 01-02-2025
By ACCESSWIRE • 06-17-2024
By GuruFocus News • 11-15-2024
By ACCESSWIRE • 09-03-2024
By ACCESSWIRE • 03-01-2024
By ACCESSWIRE • 06-25-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.